Clinical research runs on assumptions: who qualifies, which numbers matter, where studies should happen. Lately several of those assumptions have been tested, and the results say a lot about who gets access to trials and treatment.
When a formula reveals a bias
One analysis traces how removing race-adjusted variables from kidney function calculations exposed disparities in transplant eligibility. The change did more than correct one equation. It showed how bias can sit inside medical algorithms and clinical research systems for years without anyone seeing it.
The implication for trials is uncomfortable. If historical assumptions are built into eligibility criteria, they can quietly limit access for certain populations. The piece on how a single eGFR change exposed embedded patient bias argues for more inclusive research frameworks, and the case is hard to dismiss.
Old beliefs, new data
Transplant medicine offers another example. Genetic compatibility has long been treated as a central driver of survival. New trial data now suggest that long-term survival may not differ as much as previously believed, even with a genetic mismatch. Findings like this challenge traditional thinking and remind decision-makers that expanded evidence should guide practice, not habit.
The infrastructure bet
Fixing access also takes physical capacity. The United Kingdom has committed roughly $64 million to expand clinical research infrastructure and make trials easier to join, with investments across NHS providers and primary care networks. The aims are twofold: strengthen the country’s standing for global studies and improve demographic diversity among participants.
An opinion piece frames this as a bet the U.S. is too distracted to match. Whether or not that reading is right, the link between diversity and location is real, since patients can’t enroll in studies that aren’t near them.
Trust and transparency
A separate analysis examines the public exchange between Pfizer CEO Albert Bourla and FDA oncology chief Vinay Prasad, asking whether Pfizer’s response defends scientific standards or protects its product pipeline. The debate shows how tense the relationship between regulators, researchers and industry can get when transparency and commercial interest collide.
There is a practical step for sponsors in all this. Review eligibility criteria and calculation methods on a regular schedule, ask whether each exclusion is still justified by evidence, and consider where study sites sit relative to the patients who need them. These checks cost little compared with the cost of a trial whose results don’t generalize.
Conclusion
Better trials need regular audits of their own assumptions, from the formulas that decide eligibility to the geography of study sites. Each audit tends to widen the circle of patients whose data shape treatment.
This material is educational and is not a substitute for professional medical advice, diagnosis, or treatment.

Fig. 71
Fig. 79
Fig. 83